Tenaya Therapeutics Inc. (TNYA)
TNYA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TNYA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001858848 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $66.8M cash; operating cash flow -$13.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 227,928,240 (2026-10-29); 166,505,885 a year earlier; 68,111,019 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-12 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-30 |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $6.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.7M | -$18.9M | -$17.7M | $66.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $1.1M | -$43.4M | -$3.6M | $78.1M | No debt tags | Needs four quarters | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $225K | -$19.3M | -$19.2M | $80.9M | No debt tags | Needs four quarters | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | Not filed | -$20.2M | -$13.9M | $100.5M | No debt tags | Needs four quarters | 10-K 2026-03-11 |
| Q3 2025 2025-09-30 | Not filed | -$20.3M | -$15.6M | $56.3M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $0 | -$23.3M | -$15.6M | $62.7M | No debt tags | Needs four quarters | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $0 | -$26.9M | -$23.1M | $53.8M | No debt tags | Needs four quarters | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | Not filed | -$23.8M | -$18.4M | $4.3M | No debt tags | Needs four quarters | 10-K 2026-03-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-12 |
| Latest annual report | 10-K | 2026-03-11 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-10-23 |
Source: SEC EDGAR submissions feed, 354 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.1% |
| 1 month | -33.0% |
| 3 months | -52.4% |
| Year to date | -51.0% |
| 1 year | -74.5% |
| From 52-week high | -75.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AVXL | Anavex Life Sciences Corp. | $0.8176 | -12.42% | $75.8M |
| CHRS | Coherus Oncology Inc. | $0.5059 | -3.73% | $78.2M |
| NMRA | Neumora Therapeutics Inc. | $0.3695 | -13.85% | $69.4M |
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
| BDTX | Black Diamond Therapeutics Inc. | $1.53 | +4.08% | $87.9M |
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier